Patent ID: 7910605

Claim:
A method for treating symptoms associated with cognitive disorders selected from the group consisting of attention, wakefulness and memory disorders, said method comprising administering, in an amount effective to inhibit H3 receptor activity, a compound of formula (IIa) as defined below: wherein: R 1 and R 2 form together with the nitrogen to which they are attached a saturated nitrogen-containing ring with m ranging from 4 to 5 and R a-b being independently a hydrogen atom or a lower alkyl, and (i′) the chain A II selected from an unbranched alkyl group —(CH 2 ) nII — where n II is 3 (ii′) the group X″ is —O—; (iii′) the chain B II is an unbranched alkyl comprising 3 carbon atoms; and (iv′) the group Y II represents a phenyl group, unsubstituted or mono- or polysubstituted with one or more identical or different substituents selected from halogen atoms, OCF 3 , CHO, CF 3 , SO 2 N(alkyl) 2 , NO 2 , S(aryl), SCH 2 (phenyl), an unbranched or branched alkene, an unbranched or branched alkyne optionally substituted with a trialkylsilyl radical, —O(alkyl), —O(aryl), —CH 2 CN, a ketone, an aldehyde, a sulphone, an acetal, an alcohol, a lower alkyl, —CH═CH—CHO, —C(alkyl)═N—OH, —C(alkyl)═N—O(alkyl) and, —CH═NOH, —CH═NO(alkyl), —C(alkyl)=NH—NH—CONH 2 , an O-phenyl or —OCH 2 (phenyl) group, —C(cycloalkyl)=NOH, —C(cycloalkyl)=N—O(alkyl); or its pharmaceutically acceptable salts, or their optical isomers, racemates, diastereoisomers or enantiomers; to a patient in need thereof.